Phase III data on Caelyx® in ovarian cancer
Authors:
- 1 December 2001
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 37, 15-18
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicinCancer, 2001
- Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.Journal of Clinical Oncology, 1998
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal of Cancer, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Activity of Anthracyclines in Refractory Ovarian Cancer: Recent Experience and ReviewCancer Investigation, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Hexamethylmelamine in platinum-resistant ovarian cancer: How active?Gynecologic Oncology, 1992
- Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.Journal of Clinical Oncology, 1992